The estimated Net Worth of Tim B Johnson is at least $488 Tisíc dollars as of 26 December 2019. Mr. Johnson owns over 5,718 units of HTG Molecular Diagnostics Inc stock worth over $122,938 and over the last 9 years he sold HTGM stock worth over $116,964. In addition, he makes $247,848 as Executive Chairman of the Board at HTG Molecular Diagnostics Inc.
Sign up
Mr. Johnson HTGM stock SEC Form 4 insiders trading
Timothy has made over 9 trades of the HTG Molecular Diagnostics Inc stock since 2015, according to the Form 4 filled with the SEC. Most recently he sold 5,718 units of HTGM stock worth $4,117 on 26 December 2019.
The largest trade he's ever made was selling 10,621 units of HTG Molecular Diagnostics Inc stock on 10 March 2016 worth over $25,278. On average, Timothy trades about 1,288 units every 37 days since 2015. As of 26 December 2019 he still owns at least 256,121 units of HTG Molecular Diagnostics Inc stock.
You can see the complete history of Mr. Johnson stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Timothy Johnson biography
Timothy B. Johnson serves as Executive Chairman of the Board of the Company. Mr. Johnson has served as our Chief Executive Officer and as a member of our board of directors since January 2008. Mr. Johnson joined us from LVC Consulting, a consulting company, where he was a partner from April 2007 to January 2008. Prior to April 2007, Mr. Johnson spent five years in leadership roles at Ventana Medical Systems, Inc. (“Ventana”), a medical diagnostics company, prior to its acquisition by Roche Holdings, Inc. (“Roche”). At Ventana, Mr. Johnson held the positions of Senior Vice President, Global Business Services, Senior Vice President, Corporate Development and Operations, and Vice President/General Manager, Operations and Lean Systems. In these roles, Mr. Johnson’s responsibilities included product technical support, worldwide marketing, corporate development, strategic planning and manufacturing. Prior to working at Ventana, Mr. Johnson had a 12-year career at Hillenbrand Industries, Inc., a global diversified industrial company, where he held several leadership roles in the corporate offices and in the Hill-Rom Division, including Vice President, Global Marketing, Vice President/General Manager, Hill-Rom AirShields, Vice President, Operations, and Vice President, Continuous Improvement and Strategic Planning. Mr. Johnson spent part of his early career at PricewaterhouseCoopers LLP, a public accounting firm. Mr. Johnson previously served on the board of directors of Kalypto Medical, Inc. and was the Industry co-chair for the Biosciences Leadership Council of Southern Arizona. He earned a B.S. in Business from Indiana University. Our board of directors believes that Mr. Johnson’s extensive executive background in general management, strategic planning and managing operations of a diagnostic company and service as our Chief Executive Officer qualify him to serve on our board of directors.
What is the salary of Timothy Johnson?
As the Executive Chairman of the Board of HTG Molecular Diagnostics Inc, the total compensation of Timothy Johnson at HTG Molecular Diagnostics Inc is $247,848. There are 5 executives at HTG Molecular Diagnostics Inc getting paid more, with John Lubniewski having the highest compensation of $1,157,740.
How old is Timothy Johnson?
Timothy Johnson is 58, he's been the Executive Chairman of the Board of HTG Molecular Diagnostics Inc since 2019. There are 9 older and 6 younger executives at HTG Molecular Diagnostics Inc. The oldest executive at HTG Molecular Diagnostics Inc is Harry George, 71, who is the Independent Director.
What's Timothy Johnson's mailing address?
Tim's mailing address filed with the SEC is C/O HTG MOLECULAR DIAGNOSTICS, INC., 3430 E. GLOBAL LOOP, TUCSON, AZ, 85706.
Insiders trading at HTG Molecular Diagnostics Inc
Over the last 9 years, insiders at HTG Molecular Diagnostics Inc have traded over $5,630,772 worth of HTG Molecular Diagnostics Inc stock and bought 1,019,150 units worth $14,128,765 . The most active insiders traders include Plc Gsk, Holdings A/S Novo a Laurence W Lytton. On average, HTG Molecular Diagnostics Inc executives and independent directors trade stock every 64 days with the average trade being worth of $28,039. The most recent stock trade was executed by Stephen Barat on 8 June 2023, trading 888 units of HTGM stock currently worth $710.
What does HTG Molecular Diagnostics Inc do?
about htg molecular diagnostics: headquartered in tucson, arizona, htg's mission is to empower precision medicine at the local level. in 2013 the company commercialized its htg edge instrument platform and a portfolio of rna assays that leverage htg's proprietary nuclease protection chemistry. htg's product offerings have since expanded to include its htg edgeseq product line, which automates sample and targeted library preparation for next-generation sequencing. additional information is available at www.htgmolecular.com.
What does HTG Molecular Diagnostics Inc's logo look like?
Complete history of Mr. Johnson stock trades at HTG Molecular Diagnostics Inc
HTG Molecular Diagnostics Inc executives and stock owners
HTG Molecular Diagnostics Inc executives and other stock owners filed with the SEC include:
-
John Lubniewski,
President, Chief Executive Officer, Director -
John L. Lubniewski,
Pres, CEO & Director -
Shaun D. McMeans,
Sr. VP, CFO, Sec. & Treasurer -
Shaun McMeans,
Chief Financial Officer, Senior Vice President, Treasurer, Secretary -
Byron T. Lawson,
Sr. VP & Chief Commercial Officer -
Timothy Johnson,
Executive Chairman of the Board -
Byron Lawson,
Senior Vice President and Chief Commercial Financial Officer -
Lee McCracken,
Independent Director -
James LaFrance,
Independent Director -
Donnie Hardison,
Independent Director -
Michelle Griffin,
Independent Director -
Harry George,
Independent Director -
Ann Hanham,
Lead Independent Director -
Laura Beggrow,
Pres of Diagnostics -
Dr. Stephen A. Barat Ph.D.,
Sr. VP of Therapeutics -
Dr. Marian Navratil Ph.D.,
Sr. VP of R&D -
Dr. Patrick C. Roche,
Sr. VP of R&D -
Dr. Debra A. Gordon,
Sr. VP & Chief Legal Counsel -
Laura Lee Godlewski,
Sr. VP of Fin. & Admin. -
Dr. Maureen T. Cronin Ph.D.,
Sr. VP & Chief Scientific Officer -
Christopher P Kiritsy,
Director -
Stephen Barat,
Senior VP of Therapeutics -
Debra A Gordon,
V.P. and Chief Legal Counsel -
Lewis Shuster,
Director -
Plc Gsk,
10% owner -
Don M Hardison,
Director -
Holdings A/S Novo,
10% owner -
Nv Qiagen,
10% owner -
Patrick C. Roche,
SVP Research & Development -
Spaght Ventures Ii Lpfsv Ii...,
-
Donald W Grimm,
Director -
Capital Ventures Llc Senour...,
-
Tim B Johnson,
Executive Chairman -
Laurence W Lytton,
10% owner -
Thomas W. Dubensky,
Director -
Laura Lee Godlewski,
SVP Finance & Administration